Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT06220864 Recruiting - Clinical trials for Advanced Solid Tumor

SNV1521 in Participants With Advanced Solid Tumors

Start date: February 23, 2024
Phase: Phase 1
Study type: Interventional

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one.

NCT ID: NCT06220318 Recruiting - Solid Tumor Clinical Trials

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Start date: July 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II non-randomized, open-label, single-arm, multicenter study to evaluate the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors.

NCT ID: NCT06219083 Recruiting - Cancer Clinical Trials

Nutrition and Cancer Outcomes in Shaanxi Chemoradiotherapy

Start date: November 12, 2020
Phase:
Study type: Observational [Patient Registry]

The study investigates the impact of nutritional status on the clinical outcomes of cancer patients in Shaanxi Province undergoing chemoradiotherapy. It focuses on understanding how diet and nutrition affect the effectiveness and side effects of cancer treatments.

NCT ID: NCT06219018 Not yet recruiting - Clinical trials for High Risk Human Papillomavirus

Effect of Honey For CIN II

HoneyForCIN2
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase inthe normalization of CIN II lesions compared to expectant management.

NCT ID: NCT06218628 Recruiting - Clinical trials for Chronic Myelomonocytic Leukemia

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Start date: April 5, 2024
Phase: Phase 1
Study type: Interventional

This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.

NCT ID: NCT06215846 Not yet recruiting - Solid Tumor Clinical Trials

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

Start date: January 22, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With Malignant Solid Tumors. Subjects will be treated with a single dose of BioTTT001 Injection after the screening period.

NCT ID: NCT06214143 Recruiting - Clinical trials for Advanced Solid Tumors

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Start date: January 11, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors

NCT ID: NCT06212076 Not yet recruiting - Solid Tumor Clinical Trials

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

Start date: February 20, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics and initial anti-tumor activity of IPG1094 in patients with advanced solid tumors. The study will be conducted in two parts: dose escalation phase (Part A) and expansion phase (Part B).

NCT ID: NCT06211751 Not yet recruiting - Clinical trials for Hematologic Malignancy

A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy

Start date: January 2024
Phase: Phase 1
Study type: Interventional

This is an open, multi-cohort clinical study. The first phase is a dose escalation study and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the safety and preliminary efficacy of TQB3909 tablets combined with TQB3702 tablets in hematologic malignancy subjects.

NCT ID: NCT06211647 Recruiting - Clinical trials for Advanced Solid Tumor

A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors

Start date: January 2024
Phase: Phase 1
Study type: Interventional

This is a single-center, single-arm clinical study to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-XT117 injection in patients with FAP-positive advanced solid tumors. Dose escalation will be conducted to determine the Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D), and to assess dosimetry characteristics.